Decera Clinical Education Oncology Podcast

Decera Clinical Education
  • 4.9 (10)
  • COURSES
  • UPDATED MONTHLY

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

  1. JAN 30

    Individualized Hemophilia Care With Hemostatic Rebalancing Therapies

    In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers. Presenters: Angela Weyand, MD Associate Professor, Pediatric Hematology Oncology Co-Director, Combined Hematology/Gynecology Program Pediatric Medical Director, Hemophilia Treatment Center University of Michigan Medical School Ann Arbor, Michigan Guy Young, MD Director, Hemostasis and Thrombosis Center Director, Clinical Coagulation Laboratory Cancer and Blood Disease Institute Children's Hospital Los Angeles Professor of Pediatrics Division of Hematology/Oncology Department of Pediatrics University of Southern California Keck School of Medicine Los Angeles, California Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    29 min
  2. Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET

    JAN 21

    Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET

    In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including:  Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEducational resources for patients with PV, ET, or MPNsWorking with a team to incorporate SDM into clinical practiceProgram faculty: Joan How, MD Scientific and Medical Consultant Clinical Chief of Hematology Brigham and Women's Faulkner Hospital Associate Physician Brigham and Women's Hospital Assistant Professor in Medicine Harvard Medical School Boston, Massachusetts Pankit Vachhani, MD Associate Professor of Medicine Division of Hematology and Oncology University of Alabama at Birmingham O’Neal Comprehensive Cancer Center at the UAB Birmingham, Alabama Link to obtain CME/CE credit: https://bit.ly/3ZtxWJm Link to program page:  https://bit.ly/3YQKlHb Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    31 min
  3. Experts Discuss CELMoD Agents for Treating Multiple Myeloma

    12/30/2025

    Experts Discuss CELMoD Agents for Treating Multiple Myeloma

    In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including: Combination strategiesAdverse event managementWhere CELMoD agents may best fit within current and future treatment strategies Presenters:  Jesus Berdeja, MD Director of Multiple Myeloma Research Greco-Hainsworth Centers for Research Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FACP Director, Judy and Bernard Center for Myeloma, City of Hope Nason Hollingsworth Family Chair Myeloma Executive Director, Hematology, City of Hope Orange County Professor Hematology/HCT Irvine, California  Niels van de Donk, MD, PhD Professor of Hematology Department of Hematology Amsterdam UMC, Location VUmc Amsterdam, Netherlands Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/4qvRwQM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    18 min
  4. PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting

    12/30/2025

    PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting

    In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including: Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter:  Rami Komrokji, MD Senior Member, Vice Chair Section Head – Leukemia and MDS Department of Malignant Hematology H. Lee Moffitt Cancer Center Professor of Oncologic Sciences University of South Florida Tampa, Florida Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation. Link to full program:  https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    15 min
  5. Expert Highlights From the 2025 World Conference on Lung Cancer

    12/24/2025

    Expert Highlights From the 2025 World Conference on Lung Cancer

    In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials). Presenters: John Heymach, MD, PhD Chair and Professor Department of Thoracic/Head and Neck Medical Oncology Ruth Legett Jones Distinguished Chair MD Anderson Cancer Center Houston, Texas Solange Peters, MD, PhD  Professor and Director of Medical Oncology Department of Oncology University Hospital of Lausanne Lausanne, Switzerland Content based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc. Link to full program:  https://bit.ly/3L1eksI Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    25 min
  6. PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting

    12/23/2025

    PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting

    In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following: MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary diseaseCARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogeneticsSTEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapyCAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MMPresenter: Shaji K. Kumar, MD Mark and Judy Mullins Professor of Hematological Malignancies Consultant, Division of Hematology Professor of Medicine Research Chair, Division of Hematology Mayo Clinic Rochester, Minnesota Link to full program:  https://bit.ly/4995nFA Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    16 min
  7. PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

    12/19/2025

    PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

    In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including: CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FLSTARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCLPresenter:  Jeremy S. Abramson, MD, MMSc Professor of Medicine Harvard Medical School Director, Center for Lymphoma Mass General Brigham Cancer Ins Boston, Massachusetts Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation. Link to full program: https://bit.ly/4aqMobZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    14 min
  8. PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

    12/18/2025

    PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

    In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including:  LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapyAbstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infectionsAbstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand diseaseAbstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitorsPresenter: Hanny Al-Samkari, MD The Peggy S. Blitz Endowed Chair in Hematology/Oncology Co-Director, Hereditary Hemorrhagic Telangiectasia Center of Excellence Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation. Link to full program: https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    18 min
See All (225)

Ratings & Reviews

4.9
out of 5
10 Ratings

About

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Information

You Might Also Like